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ABSTRACT 
Background Exercise effects in cancer patients often appear modest, possibly because 
interventions rarely target patients most in need. This study investigated the moderator effects 
of baseline values on the exercise outcomes of fatigue, aerobic fitness, muscle strength, 
quality of life (QoL) and self-reported physical function (PF) in cancer patients during and 
post-treatment.  
Methods Individual patient data from 34 randomized exercise trials (n=4,519) were pooled. 
Linear mixed-effect models were used to study moderator effects of baseline values on 
exercise intervention outcomes, and to determine whether these moderator effects differed by 
intervention timing (during versus post-treatment). 
Results Moderator effects of baseline fatigue and PF were consistent across intervention 
timing, with larger effects in patients with worse fatigue (p=0.05) and worse PF (p=0.003). 
Moderator effects of baseline aerobic fitness, muscle strength and QoL differed by 
intervention timing. During treatment, effects on aerobic fitness were larger for patients with 
better baseline aerobic fitness (p=0.002). Post-treatment, effects on upper (p<0.001) and 
lower (p=0.01) body muscle strength and QoL (p<0.001) were larger in patients with worse 
baseline values.  
Conclusion Although exercise should be encouraged for most cancer patients during and post 
treatments, targeting specific subgroups may be especially beneficial and cost-effective. For 
fatigue and PF, interventions during and post-treatment should target patients with high 
fatigue and low PF. During treatment, patients experience benefit for muscle strength and 
QoL regardless of baseline values, however, only patients with low baseline values benefit 
post-treatment. For aerobic fitness, patients with low baseline values do not appear to benefit 
from exercise during treatment. 
5 
 
INTRODUCTION 
There is evidence from randomized controlled trials (RCTs) that exercise has beneficial 
effects on fatigue, physical fitness, quality of life (QoL) and self-reported physical function 
(PF) during and post cancer treatment(1-7). The magnitude of these effects, however, is often 
small to moderate(2, 3, 8-10). One explanation for these modest effects may be the lack of 
specifically targeting those patients who are most likely to benefit from exercise 
interventions. For other types of supportive care interventions, such as psychosocial 
interventions, larger effects on distress and QoL are often found in patients with higher 
distress(11-13) and lower QoL(14). Consequently, some RCTs have screened for distress 
prior to enrolling patients into a psychosocial intervention(15-18). In our previous meta-
analysis on individual patient data (IPD), we found that 36% of RCTs evaluating the effects 
of psychosocial interventions specifically targeted patients with psychosocial symptoms and, 
in general, these RCTs showed larger intervention benefits(19). Thus, targeting psychosocial 
interventions to patients with worse symptoms and QoL seems useful and economical. 
Whether this principle is also the case for exercise interventions is unknown.  
Only a limited number of exercise intervention studies have evaluated the moderator 
effect of baseline fatigue, physical fitness (i.e. aerobic fitness and muscle strength), QoL and 
PF on intervention effects in patients with cancer(20-24). Studying these moderator effects 
may help to identify subgroup of patients for whom exercise interventions are especially 
beneficial or futile(25, 26). Results from previous RCTs have shown that the effects of 
exercise interventions on fatigue were larger in patients with higher baseline fatigue(22, 23). 
Also, exercise intervention effects on QoL were larger in patients who had completed 
chemotherapy with higher baseline fatigue(20), and in patients with lymphoma with lower 
baseline QoL(21). Comparably, in patients undergoing allogeneic stem cell transplantations, 
larger effects on physical fitness were found in unfit patients compared with fit patients(27).  
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The aims of exercise interventions differ across the cancer continuum. Exercise 
interventions during primary cancer treatment, especially chemotherapy, typically aim to 
prevent declines in functioning and to ameliorate treatment side-effects, while exercise 
interventions post-treatment aim to improve functioning(28). Therefore, it may also be 
important to identify when targeting exercise interventions to baseline values of fatigue, 
physical fitness, QoL and PF would be most useful. Since it may be important to prevent 
declines in functioning during primary cancer treatment in all patients regardless of baseline 
functioning, we studied whether the benefit from exercise during cancer treatment was 
independent of baseline value. Conversely, post-treatment, we hypothesized larger benefits on 
fatigue, physical fitness, QoL and PF in patients with worse baseline values. 
Using data collected in the Predicting OptimaL cAncer RehabIlition and Supportive 
care (POLARIS) study(26), this IPD meta-analysis aimed to study the moderator effects of 
baseline values on the exercise response for fatigue, physical fitness, QoL and PF, and to 
examine whether these moderator effects differ by intervention timing (during versus post-
treatment).  
 
METHODS 
Study inclusion and characteristics 
The POLARIS study is an international collaboration in which IPD of RCTs were harmonized 
for pooled analyses(26). POLARIS included RCTs that evaluated the effects of exercise 
and/or psychosocial interventions on QoL compared to a wait-list, usual care or attention 
control group in adult (≥18 years) patients with cancer. Eligible studies were identified via 
systematic searches in electronic databases, reference checking of systematic reviews, meta-
analyses and via personal communication with collaborators, colleagues and other experts in 
the field. Details of the study design, procedures, search strategies, study inclusion, sample 
7 
 
and quality have been published previously(4, 26). The study protocol was registered in 
PROSPERO in February 2013 (CRD42013003805). 
IPD from 34 (n= 4,519 patients) of 69 RCTs (response 49%) evaluating the effects of 
exercise were included(4). These 34 RCTs were a representative sample of the published 
RCTs evaluating exercise intervention effects on QoL and PF(4). The moderator effects of 
demographic, clinical, and intervention-related variables for QoL(4), physical fitness(6), and 
fatigue(7) are reported elsewhere. 
 
Exercise interventions 
Details of the different exercise interventions have been published previously(4). Study-, 
intervention-, and exercise-characteristics of included studies and pre-intervention values of 
fatigue, physical fitness, QoL, and PF are presented in Table 1. Of 34 RCTs, 17(29-45) 
focused on patients with breast cancer, five(46-50) on various cancer types, five(23, 51-54) on 
prostate cancer, three(55-57) on hematological cancer, one(58) on colorectal cancer, and 
one(59) on lung cancer. Two RCTs(60-63) included patients with breast and colon cancer, of 
which results were published in separate reports. Three RCTs specifically targeted patients 
with menopausal symptoms(33), lymphedema (risk)(42) or multiple physical or psychosocial 
problems(49), but no studies specifically targeted patients with fatigue, low fitness, or poor 
QoL. Fourteen(23, 32, 35, 36, 38-40, 43-45, 47, 52-54) RCTs excluded patients who 
participated in regular physical activity or exercise.  
 
Outcome variables 
The current analyses used outcomes assessed at pre- and post-intervention. Table 2 presents 
the different measures used to assess the outcomes. Fatigue, QoL and PF were assessed by 
self-report. Physical fitness was measured objectively by assessing aerobic fitness, upper 
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(UBMS) and lower body muscle strength (LBMS). To allow pooling of the different measures 
or questionnaires, we recoded the individual scores (pre- and post-intervention) into z-scores 
by subtracting the mean pre-intervention score from the individual score and dividing the 
result by the standard deviation (SD) pre-intervention per measurement instrument. 
Subsequently, the pooled z-scores were used for further analyses.  
 
Statistical analysis 
Moderator effects of the baseline value of the outcome were studied using a one-step 
approach. Linear mixed model analyses with a two-level structure (1:patient, 2:study) were 
used to consider the clustering of patients within studies by using a random intercept on study 
level. The post-intervention value (z-score) of the outcome was regressed on the intervention, 
and adjusted for the baseline value (z-score) to limit regression to the mean(64, 65). 
Moderator effects were examined by adding the interaction term of the moderator variable 
with the intervention into the regression model. We added a 3-way interaction of 
intervention×baseline value×intervention timing, along with the three corresponding 2-way 
interactions to the model, and intervention timing. A significant 3-way interaction indicates 
that the moderator effects of the baseline value of the outcome differ between interventions 
offered during versus post cancer treatment. In this case, we tested the moderator effects 
separately for interventions during and post cancer treatment. In case the 3-way interaction 
was not significant, the moderator effect of the baseline value (baseline value×intervention) 
was tested in the total group (i.e. both during and post-treatment). We used the likelihood 
ratio test to compare models with and without interaction terms. Additionally, regression 
coefficients, 95% confidence intervals (CI), and corresponding p-values of the interaction 
term were examined. In case the model improved significantly by adding the interaction term 
or in case the interaction term was significant, stratified analyses were conducted for 
9 
 
intervention timing, and for subgroups of baseline fatigue, aerobic fitness, UBMS, LBMS, 
QoL and PF. For 2-way interactions, we considered p≤0.05 as significant. For 3-way 
interactions, we chose a cut-off of p≤0.10 to reduce the risk for missing potential moderator 
effects. For the stratified analyses, we categorised the baseline values into four groups of SD 
scores (<-1SD vs.-1SD to mean vs. ≥mean to 1SD vs.>1SD). The SD scores can be translated 
to the scores of the original measurement instrument of interest. All analyses were adjusted 
for age, sex and cancer type. Because supervised exercise showed to have larger effects on all 
outcomes compared to unsupervised exercise(4, 6, 7), we conducted sensitivity analyses in 
the subgroup of patients that had received a supervised exercise intervention.  
 
RESULTS 
Baseline values of fatigue, physical fitness, QoL, and PF are presented in Table 2. As also 
reported previously(4, 6, 7), linear mixed model analyses showed that exercise significantly 
reduced fatigue (β=-0.17,95%CI=-0.22;-0.12,p<0.001; I2 for heterogeneity=37.83,p=0.02) and 
improved aerobic fitness (β=0.28,95%CI=0.22;0.33,p<0.001;I2=81.02,p<0.001), UBMS 
(β=0.18,95%CI=0.13;0.24,p<0.001;I2=65.58,p<0.001), LBMS 
(β=0.27,95%CI=0.22;0.33,p<0.001;I2=84.69,p<0.001), QoL 
(β=0.15,95%CI=0.10;0.19,p<0.001;I2=18.07,p=0.18) and PF 
(β=0.18,95%CI=0.13;0.23,p<0.001;I2=38.10,p=0.01) overall, compared to the control 
condition. 
Three-way interactions were (borderline) significant for aerobic fitness 
(pinteraction=0.04), UBMS (pinteraction=0.10), LBMS (pinteraction=0.05) and QoL (pinteraction=0.07), 
but not for fatigue (pinteraction=0.89) and PF (pinteraction=0.65). These interactions indicate that 
the moderator effects of the baseline values of aerobic fitness, UBMS, LBMS, and QoL 
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differed between exercise interventions offered during versus post cancer treatment, whereas 
they did not differ for fatigue and PF (Table 3).  
Across intervention timing, baseline PF significantly moderated the exercise 
intervention effect on PF (pinteraction=0.003) and baseline fatigue moderated the exercise 
intervention effects on fatigue (pinteraction=0.05). The exercise intervention effect on PF was 
significant when baseline PF was less than 1SD above the mean (Table 4;Figure 1). The 
exercise intervention effect on fatigue was significant when baseline values of fatigue were 
equal or larger than 1SD below the mean (Table 4;Figure 1).  
For exercise interventions during treatment, we found that the exercise intervention 
effect on aerobic fitness was moderated significantly by its baseline value (pinteraction=0.002, 
Table 2), such that patients with low baseline aerobic fitness (<-1 SD below mean) did not 
significantly benefit from the exercise intervention, whereas larger benefits were found in 
patients with higher aerobic fitness at baseline (Table 4;Figure 2).  
For exercise interventions post-treatment, baseline values of UBMS (pinteraction <0.001), 
LBMS (p=0.01), and QoL (pinteraction<0.001) significantly moderated the exercise intervention 
effects (Table 3). Stratified analyses of the exercise intervention effects post-treatment 
showed larger effects on UBMS and LBMS for patients with baseline values below the mean, 
whereas effects on QoL were particularly pronounced for patients with baseline values of at 
least 1SD below the mean (Table 4;Figure 3). 
Results of the sensitivity analyses in patients who had received supervised exercise 
interventions were only slightly different. The moderator effect of the baseline value of 
aerobic fitness during cancer treatment was less pronounced (βinteraction=0.07, 95%CI=-
0.01;0.16,p=0.08). Additionally, for UBMS, the difference in the moderator effect of baseline 
values between interventions during and post cancer treatment was larger (β3-way interaction=-
0.21,95%CI=-0.32;-0.09,p<0.001), but it did not change the conclusions. 
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DISCUSSION 
In this IPD-meta-analysis, we investigated whether the effects of exercise interventions during 
treatment on fatigue, physical fitness, QoL and PF were equally effective across patients with 
different baseline values, and whether the effects of exercise interventions on these outcomes 
post-treatment were larger in patients with worse baseline values. We found that baseline 
values did not significantly moderate the exercise intervention effect on these outcomes 
during cancer treatment except for aerobic fitness. For exercise interventions post cancer 
treatment, baseline values of UBMS, LBMS, and QoL moderated the exercise intervention 
effect on these outcomes, with stronger effects in patients with worse baseline values, and no 
significant benefits for patients with baseline values >1 SD above the mean. For aerobic 
fitness, we found larger effects of exercise interventions during treatment in patients with 
higher baseline aerobic fitness, whereas baseline values did not moderate the exercise 
intervention effects post-treatment. Larger effects on fatigue and PF were found for patients 
with worse baseline fatigue and PF, both during and post-treatment.  
Our findings may have important clinical implications for identifying which subgroups 
of patients may benefit the most or the least from exercise during and post cancer treatment 
for these specific outcomes. Although exercise should be encouraged for most patients with 
cancer(66), our results indicate that depending on the aim of the exercise intervention, certain 
subgroups of patients may not gain benefits for certain outcomes. Exercise interventions 
during treatment are effective in maintaining UBMS, LBMS, and QoL, regardless of the 
baseline value. Offering exercise interventions post-treatment to patients with a relatively 
high UBMS, LBMS and QoL (>1 SD above the mean on respective measures) does not 
appear to further improve these outcomes. A previous RCT in patients with lymphoma during 
or post chemotherapy also found larger effects on QoL in patients with lower baseline 
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values(21), but this study did not disentangle differences in the moderator effects across 
timing of intervention delivery.  
Our finding that exercise interventions during cancer treatment showed better effects 
on aerobic fitness in patients with higher baseline aerobic fitness was unexpected and 
counterintuitive. The stratified analysis showed, however, that it was only patients with values 
lower than 1 SD below the mean who did not benefit significantly. This finding suggests that 
a minimum level of aerobic fitness may be needed to obtain an aerobic fitness response to an 
exercise intervention during cancer treatment. Perhaps, despite often being tailored to an 
individual’s capacity, exercise interventions during intensive cancer treatments may be too 
difficult for patients with low aerobic fitness, resulting in lower adherence. Previous studies 
have found aerobic fitness to be a predictor of exercise adherence during chemotherapy(67-
69). Lower adherence to exercise during chemotherapy in patients with lower aerobic fitness 
may be caused by more comorbidities, toxicities, illness or fatigue(67, 69, 70), as well as by 
limited exercise history(71) or low muscle strength(69). This may particularly be the case for 
unsupervised exercise, as our sensitivity analyses indicated that the moderator effect of 
baseline aerobic fitness was less pronounced for supervised exercise. A second possible 
explanation may be an inadequate exercise stimulus to improve aerobic fitness, either because 
exercise specialists may be too conservative when tailoring the exercise intervention to 
patients with low fitness during treatment, or that, related to variations in methods used to 
prescribe exercise intensity, patients may not be able to reach prescribed intensity targets(72, 
73). Future studies should clarify if and how patients with low aerobic fitness can adhere and 
benefit from exercise interventions during cancer treatment. They should study how to better 
tailor exercise interventions during treatment to patients with low aerobic fitness, or whether 
it is better to offer these patients an aerobic exercise intervention after completion of cancer 
treatment, as this was shown to be effective for patients with various baseline fitness levels in 
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the current meta-analysis. The discrepancy between findings for muscle strength and aerobic 
fitness may indicate that it is more feasible for patients with low muscle strength to perform 
resistance exercises during cancer treatment than for patients with low aerobic fitness to 
perform aerobic exercises.  
In contrast to objective measures of physical fitness, larger exercise intervention 
effects were found for self-reported PF for patients with worse baseline values, regardless of  
intervention timing. Although physical fitness and PF are related, they are not the same 
constructs, and may therefore produce different results(74). Our data suggest that exercise 
interventions may improve patient reports of PF during and post cancer treatment in patients 
with low PF, whereas the influence of the patient’s objectively assessed baseline muscle 
strength and aerobic fitness on the intervention effects on these outcomes differed across 
intervention timing. This non-linear relationship between objective functional capacity (i.e. 
physical fitness) and patient-reported performance (i.e. physical function) indicates that 
improved capacity is not necessarily a prerequisite for improved patient-reported 
functioning(75), and that improving PF may also require behavioral changes, adaptations to 
the physical environment or support from the social environment(76). Additionally, 
symptoms such as fatigue may also influence self-reported functioning, regardless of physical 
fitness(77). 
Our finding that patients with worse baseline fatigue had larger fatigue reductions 
supports results of previous explorative studies in patients who completed cancer 
treatment(20, 22), and in patients during androgen deprivation therapy(23). This finding 
highlights the importance of targeting subgroups of patients whose fatigue is 1SD worse than 
the mean value, as they may benefit the most from exercise with respect to fatigue. Results 
showed that exercise will neither benefit PF of patients with high baseline values (>1SD 
above mean), nor will it benefit fatigue in patients with low symptoms of fatigue (<1SD 
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below mean). Obviously, post cancer treatment, there is no or little room for improvement in 
these symptoms if they are not present or only marginally present. Perhaps during treatment, 
patients with no or minimal symptoms (often post-surgery) are not prone to developing them, 
and therefore, no significant preventive effects of exercise are found for these measures. The 
lack of appropriately targeted interventions in previous studies may have underestimated the 
effects of exercise, particularly on fatigue and PF, and post-treatment. Future studies should 
therefore consider targeting exercise interventions to specific subgroups of patients. More 
recent exercise studies have begun to target patients with symptoms such as arthralgia(78), 
and fatigue(79), and to tailor exercise prescriptions to key physiological characteristics, such 
as bone health and muscle strength(80). 
Strengths of this IPD meta-analyses include the large sample size, allowing us to 
assess the moderator effects with interaction tests, using uniform analytic procedures across 
all RCTs, and to conduct subsequent stratified analyses. However, some caution is warranted 
in generalizing these results to all patients with cancer. The IPD study population may be 
somewhat biased towards patients with breast cancer and to those who are more interested in 
exercise and may have fewer comorbidities(81), less fatigue(63, 81, 82) and distress(83), and 
higher QoL(82). Additionally, this paper focused exclusively on fatigue, physical fitness, QoL 
and PF. Moderator effects of baseline values of other relevant outcomes, including 
depression, sleep, and menopausal symptoms, and long term health outcomes (e.g. 
cardiovascular risk, cancer recurrence, and survival) should be investigated in future studies. 
Finally, there was considerable heterogeneity in the content of the exercise interventions, the 
measures to assess the outcomes with potentially different psychometric properties and 
responsiveness, and the types of cancer treatments. Therefore, our findings on moderator 
effects of baseline values should be confirmed in large single studies with homogeneous 
patient populations, uniform treatment protocols, and validated outcome measures. 
15 
 
 
In conclusion, the effects of exercise interventions post cancer treatment on UBMS, LBMS 
and QoL appear to be larger in patients with worse baseline values, whereas exercise 
interventions during cancer treatment are equally effective for these outcomes, regardless of 
baseline values. This finding indicates that, when using exercise for rehabilitation after cancer 
treatments, it may be useful to target specific exercise interventions to patients with low 
muscle strength and poor QoL. Likewise, when aiming to benefit fatigue and PF during and 
post cancer treatment, exercise interventions should be targeted to patients with high levels of 
fatigue and low levels of PF, as they show the most benefits on these outcomes. Further 
research is necessary to identify how to improve aerobic fitness in patients with low aerobic 
fitness during cancer treatment. Although exercise is likely beneficial for most patients with 
cancer, exercise interventions targeted to specific subgroup of patients stand to have the 
largest impact on patient outcomes and the highest cost-effectiveness. 
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Table 1. Descriptives of study-, intervention-, and exercise-characteristics of included studies (n=34),  and 
baseline values of outcomes of participants (n=4,519). 
 Number of studies Number of participants 
in these studies 
Study characteristics   
Country   
     United States 8 860 
     The Netherlands 7 1360 
     Australia 6 899 
     Canada 4 518 
     Germany 4 367 
     United Kingdom 3 360 
     Spain 1 16 
     Norway 1 139 
Sample size   
     0 – 100 13 799 
     >100 – 200  13 1678 
     >200 – 300  7 1712 
     >300 1 330 
Cancer typea   
     Breast cancer 19 2754 
     Mixed cancer types 5 819 
     Prostate cancer 5 426 
     Haematological 3 311 
     Colon cancer 3 158 
     Lung cancer 1 51 
Intervention characteristics   
Intervention timing   
     Pre-during-post cancer treatment 1 80 
     During and/or post cancer treatment 3 418 
     During cancer treatment 13 1808 
          During chemotherapy 4 820 
          During radiotherapy 1 141 
          During chemotherapy and/or radiotherapy  4 524 
          During androgen deprivation therapy 4 326 
     Post cancer treatment 17 2213 
Intervention delivery modeb   
     Supervised 25 3091 
     Unsupervised 10 1513 
Intervention Duration   
     ≤ 12 weeks 13 1523 
     12 – 24 weeks 11 1824 
     >24 weeks 10 1172 
Type of control groupc   
     Usual care 19 2582 
     Wait-list 9 1364 
     Attention Control 7 607 
Exercise characteristics   
Frequency, times per weekb   
     2 19 2742 
     3 – 4  8 1081 
     ≥ 5 6 730 
     Unknown 1 51 
Intensityd   
     Low-moderate 2 327 
     Moderate 13 1528 
     Moderate-high 16 1926 
     High 2 389 
     Unknown 3 525 
Typee   
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     Aerobic exercise 12 1374 
     Aerobic + resistance exercise 16 2253 
     Resistance exercise 5 774 
     Resistance + impact exercise 4 332 
Mean session durationf   
     0 – 30 min 10 1486 
     >30 – 60 min 19 2479 
     >60 min 4 502 
     Unknown 2 137 
Outcome measure   
     Fatigue 31 4366 
     Aerobic fitness 21 2742 
     Upper body muscle strength 19 2546 
     Lower body muscle strength 18  2258 
     Quality of life     34 4519 
     Physical function 34 4519 
an+2, because two(60-63)RCTs included patients with breast and colon cancer with separate reports. bn+1, 
because one RCT(62) included both a supervised (2 times per week) and an unsupervised (5 times per week) 
exercise study arm. cn+1 because one RCT(32) included both a usual care and an attention control group. dn+2, 
because one RCT(62) included a moderate intensity and moderate-high intensity study arm, and another 
RCT(48) included both a moderate and a vigorous intensity exercise study arm.en+3, because one RCT(62) had 
combined aerobic and resistance exercise study arm and an aerobic exercise study arm, one RCT(31) had an 
aerobic exercise and a resistance exercise study arm, and one RCT(23) had a combined resistance and aerobic 
exercise study arm and a combined resistance and impact loading exercise arm.fn+1 because one RCT(62) had a 
study arm with 30 min/session and one with 60min/session.
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Table 2. Instruments used to assess the outcome measures and the baseline values. 
 Number of studies (references) Mean (SD)  
total samplea 
Mean (SD)  
during treatment 
Mean (SD)  
post-treatment 
Fatigue (n=4,272)     
     FACIT  8 (30, 31, 34, 38, 41, 51, 55, 58) 37.1 (11.0) 36.0 (11.5) 39.1 (9.6) 
     MFI, general fatigue   6 (48, 49, 56, 57, 60-62) 12.1 (4.3) 10.7 (4.1) 13.5 (4.0) 
     EORTC QLQ-C30, fatigue  5 (23, 37, 50, 52, 53) 29.1 (22.3) 24.9 (19.3) 32.3 (23.8) 
     SF-36, vitality 4 (29, 33, 36, 42) 55.3 (18.7) 50.0 (9.5) 55.7 (19.2) 
     Schwartz Cancer Fatigue Scale  3 (44, 45, 54) 10.4 (3.9) 9.8 (4.0) 10.6 (3.9) 
     FAQ, total  2 (40, 43) 38.4 (21.8) 38.4 (21.8) N/A 
     Revised Piper Fatigue Scale  2 (32, 47) 2.7 (1.9) 2.4 (2.0) 3.1 (1.8) 
     CIS, total  1 (46) 57.0 (26.1) 57.0 (26.1) N/A 
     Missing, n=94     
Aerobic fitness (n=2,322)     
    PeakVO2, ml/kg/min  11 23.5 (7.2) 22.4 (7.1) 24.2 (7.0) 
         Directly 8 (30, 31, 37, 48, 55, 56, 58, 60, 61)    
        Indirectly via a submaximal exercise test  2 (32, 50)    
        Directly or indirectly, based on patient’s    
         Preference 
1 (47)    
    400 meter walk test, s  4 (23, 51-53) 272.6 (49.4) 268.4 (50.4) 282.3 (53.8) 
    6 minute walk test, m  2 (57, 59) 441.9 (109.2) N/A 441.9 (109.2) 
    12 minute walk test, m   1 (38) 986.3 (222.8) 986.3 (222.8) N/A 
    Endurance test at 70% of Wmax, s  1 (62) 743.7 (530.0) 743.7 (530.0) N/A 
    Modified Balke test, s 1 (58) 367.3 (291.1) 364.0 (300.1) 383.2 (269.5) 
    Steptest, heartrate in beats per minute 1 (34) 120.4 (16.0) 120.4 (16.0) N/A 
    Missing: n=2     
Upper body muscle strength (n=2,255)     
     Chest press, 1 repetition maximum in kg 10 (23, 31, 39, 42, 51-54) 34.0 (16.4) 44.2 (16.1) 24.5 (9.5) 
     Handgrip strength, in kg  4 (30, 48, 56, 60, 61) 35.8 (10.3) 32.9 (7.4) 37.3 (11.2) 
     Elbow flexion with handheld dynamometer, in Nm  1 (62) 29.9 (12.4) 29.9 (12.4) N/A 
     Chest press, number of repetitions at 30-35% body mass 1 (35) 0.1 (0.5) N/A 0.1 (0.5) 
     Sum upper body muscle strength (4 groups), in N 1 (57) 154.1 (50.6) N/A N/A 
     Sum of left and right grip strength, kg 1 (58) 70.5 (22.5) 71.9 (21.8) 68.9 (23.6) 
     Upright row and shoulder press, stage  1 (34) 6.8 (3.1) 6.8 (3.1) N/A 
     Missing, n=79     
Lower body muscle strength (n=2,056)     
    Leg press, 1 repetition maximum in kg  9 (23, 39, 42, 44, 45, 51-54) 101.9 (43.6) 124 (51.6) 89.8 (32.7) 
    Quadriceps torque, in Nm  5 (32, 40, 43, 56, 60, 61) 104.6 (35.7) 103.3 (28.5) 107.5 (47.8) 
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    Leg extension, 1 repetition maximum in kg 1 (31) 54.9 (26.6) 54.9 (26.6) N/A 
    Knee extension with handheld dynamometer, in Nm  1 (62) 67.6 (19.1) 67.6 (19.1) N/A 
    Leg press, number of repetitions at 100-110% body mass 1 (35) 13.5 (7.2)  N/A 13.5 (7.2) 
    Sum of lower body muscle strength (4 groups), in N 1 (57) 186.1 (58.7) N/A N/A 
    Missing: n= 107     
Quality of life (n=4,419)     
     EORTC-QLQ-C30, global QoL 17 (23, 35, 40, 43-46, 48-54, 56, 59-61) 69.6 (19.0) 71.7 (18.7) 67.8 (18.7) 
     FACT-G, total score 10 (29-32, 34, 36, 38, 41, 55, 58) 81.3 (14.3) 79.2 (14.6) 84.1 (13.5) 
     SF-36, general health 6 (33, 37, 42, 44, 45, 47) 66.3 (19.6) 52.6 (13.9) 68.7 (19.8) 
     Cares-SF, global QoL 1 (39) 48.2 (9.1) N/A 48.2 (9.1) 
     Missing, n=100     
Physical Function (n=4,433)     
     EORTC-QLQ-C30, physical function 17 (23, 35, 40, 43-46, 48-54, 56, 59-61) 83.4 (16.1) 86.7 (14.5) 79.6 (16.5) 
     FACT-G, physical well-being 10 (29-32, 34, 36, 38, 41, 55, 58) 21.9 (5.4) 20.6 (5.9) 23.7 (3.9) 
     SF-36, physical function 6 (33, 37, 42, 44, 45, 47) 81.6 (17.6) 85.6 (14.4) 80.9 (18.0) 
     Cares-SF, physical function 1 (39) 46.6 (7.0) N/A 46.6 (7.0) 
     Missing, n= 86     
aThe SD values of the total group can be used to interpret the effect sizes, which are expressed in SD scores.  
Abbreviations: CARES-SF=Cancer Rehabilitation Evaluation System-Short Form; CIS=Checklist Individual Strength; EORTC QLQ-C30= European Organisation for 
Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; FACIT= Functional Assessment of Chronic Illness Therapy – Fatigue;  FACT-G= Functional 
Assessment of Cancer Therapy-General; FAQ= Fatigue Assessment Questionnaire; MFI= Multidimensional Fatigue Inventory; N/A= not applicable; peakVO2= peak oxygen 
uptake; SF-36= Short Form-36 Health Survey.  
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Table 3. Moderator effects of baseline values for the total group or stratified for interventions during and post cancer treatment in case of significant moderator effect of 
timing.  
Variable 3-way interaction Moderator effect in total group Moderator effect during cancer treatment Moderator effect post cancer treatment 
 p of LR test  βinteraction (95%CI)  P of LR test βinteraction (95%CI) P of LR test βinteraction (95%CI) P of LR test βinteraction (95%CI) 
Fatigue 0.89 0.007 (-0.10; 0.11) 0.05# -0.05 (-0.10; 0.000) - - - - 
Aerobic fitness 0.04* -0.11 (-0.22; -0.004)* - - 0.002* 0.11 (0.04;0.18) 0.95 0.002 (-0.08;0.08) 
UBMS 0.10# -0.10 (-0.21; 0.02) - - 1.00 -0.00 (-0.09;0.09) <0.001* -0.11 (-0.17;-0.05) 
LBMS  0.05# -0.12 (-0.24; 0.002) - - 0.57 0.02 (-0.06;0.10) 0.01* -0.10 (-0.18;-0.02) 
QoL 0.07# -0.09 (-0.19;0.006) - - 0.38 -0.03 (-0.11;0.04)  <0.001* -0.13 (-0.19;-0.06) 
PF 0.65 -0.02 (-0.12;0.08) 0.003* -0.07 (-0.12;-0.03) - - - - 
*p≤0.05,  #0.05 <p≤ 0.10. Analyses are adjusted for age, sex and cancer type. 
Abbreviations: CI= confidence intervals; LBMS= lower body muscle strength; LR= likelihood ratio; PF= physical function; QoL= quality of life; UBMS= upper body muscle 
strength 
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Table 4. Exercise intervention effects on outcomes for the total group and stratified per subgroup based on baseline standard deviation score, in case of significant moderator 
effects of the baseline values.  
 
 
Overall effect <1 SD below mean  1 SD below mean to mean  mean to 1SD above mean >1 SD above mean  P for trend 
 β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)  
All studies       
Fatiguea -0.17 (-0.22; -0.12)* 
(n=3846) 
 -0.03 (-0.13; 0.08) 
(n=649) 
-0.17 (-0.25; -0.09)* 
(n=1430) 
-0.20 (-0.30; -0.11)* 
(n=1124) 
-0.22 (-0.37; -0.07)* 
(n=643) 
<0.001 
PF 0.18 (0.13; 0.23)* 
(n=3984) 
0.27 (0.11; 0.42)* 
(n=649) 
0.22 (0.11; 0.34)* 
(n=890) 
0.19 (0.12; 0.25)* 
(n=1727) 
0.03 (-0.07; 0.12) 
(n=718) 
<0.001 
During cancer 
treatment 
      
Aerobic fitness 0.25 (0.18; 0.33)* 
(n= 1374) 
 0.07 (-0.12; 0.26) 
(n=211) 
0.20 (0.09 0.31)* 
(n=510) 
0.32 (0.22; 0.43)* 
(n=453) 
0.38 (0.15; 0.60)* 
(n=200) 
<0.001 
UBMS 0.25 (0.16; 0.35)* 
(n=1106) 
- - -   
LBMS 0.29 (0.20; 0.37)* 
(n=1019) 
- - -   
QoL 0.15 (0.07; 0.22)* 
(n=1914) 
- - -   
Post cancer 
treatment 
      
Aerobic fitness 0.33 (0.24; 0.41)* 
(n=843) 
- - -   
UBMS 0.10 (0.04; 0.15)* 
(n=904) 
0.21 (0.12; 0.30)* 
(n=168) 
0.19 (0.13; 0.25)* 
(n=458) 
-0.04 (-0.16; 0.08) 
(n=180) 
-0.06 (-0.17; 0.06) 
(n=98) 
<0.001 
LBMS 0.26 (0.18; 0.34)* 
(n=646) 
0.38 (0.25; 0.51)* 
(n=89) 
0.30 (0.21; 0.39)* 
(n=363) 
0.20 (-0.01;0.40)# 
(n=129) 
0.03 (-0.33; 0.40) 
(n=65) 
<0.001 
QoL 0.15 (0.09; 0.21)* 
(n=1960) 
0.36 (0.17; 0.55)* 
(n=311) 
0.19 (0.06; 0.32)* 
(n=538) 
0.12 (0.03; 0.21)* 
(n=741) 
-0.02 (-0.13; 0.08) 
(n=370) 
0.012 
*p≤0.05,  #0.05 <p≤ 0.10. Analyses are adjusted for age, gender and cancer type 
aHigher scores on the fatigue scale indicate more fatigue 
Abbreviations: CI= confidence intervals; df= degrees of freedom; LBMS= lower body muscle strength; PF= physical function; QoL= quality of life; SD= standard deviation; 
UBMS= upper body muscle strength 
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Figure 1. Stratified subgroup effect of exercise interventions based on pre-intervention 
standard deviation (SD) score for baseline values of physical function (black bars) and fatigue 
(white bars) during and post cancer treatment. 
 
Figure 2. Stratified subgroup effects of exercise interventions based on pre-intervention 
standard deviation (SD) score for the baseline value of aerobic fitness during treatment. 
 
Figure 3. Stratified subgroup effects of exercise interventions based on pre-intervention 
standard deviation (SD) score for baseline values of upper body muscle strength (black bars), 
lower body muscle strength (white bars) and quality of life (dashed bars) post cancer 
treatment. 
 
 
